In addition, the tumor cells activate TGF-β signaling, which alters a major component of the TME known as CAFs, which in turn alters the extracellular matrix (ECM) in a way that rejects immune cells and may affect immunotherapy responses (146). Here, TGFB1 is linked to neoplasm.